

Supplemental Appendix

Title: Treatment and long-term outcome in primary distal Renal Tubular Acidosis.

Authors: Sergio Camilo Lopez-Garcia^{1,2}, Francesco Emma⁴, Stephen B Walsh², Marc Fila⁵, Nakysa Hooman⁶, Marcin Zaniew⁷, Aurélia Bertholet-Thomas⁸, Giacomo Colussi⁹, Kathrin Burgmaier¹⁰, Elena Levchenko¹¹, Jyoti Sharma¹², Jyoti Singhal¹², Neveen A. Soliman¹³, Gema Ariceta¹⁴, Biswanath Basu¹⁵, Luisa Murer¹⁶, Velibor Tasic¹⁷, Alexey Tsygin¹⁸, Stéphane Decramer¹⁹, Helena Gil-Peña²⁰, Linda Koster-Kamphuis²¹, Claudio La Scola²², Jutta Gellermann²³, Martin Konrad²⁴, Marc Lilien²⁵, Telma Francisco²⁶, Despoina Tramma²⁷, Peter Trnka^{28,29}, Selçuk Yüksel³⁰, Maria Rosa Caruso³¹, Milan Chromek³², Zelal Ekinci³³, Giovanni Gambaro³⁴, Jameela A. Kari³⁵, Jens König²⁴, Francesca Taroni³⁶, Julia Thumfart²³, Francesco Trepiccione³⁷, Louise Winding³⁸, Elke Wühl³, Ayşe Ağbaş³⁹, Anna Belkevich⁴⁰, Rosa Vargas-Poussou⁴¹, Anne Blanchard⁴¹, Giovanni Conti⁴², Olivia Boyer⁴³, Ismail Dursun⁴⁴, Ayşe Seda Pınarbaşı⁴⁴, Engin Melek⁴⁵, Marius Miglinas⁴⁶, Robert Novo⁴⁷, Andrew Mallett^{29,48}, Danko Milosevic⁴⁹, Maria Szczepanska⁵⁰, Sarah Wente⁵¹, Hae Il Cheong⁵², Rajiv Sinha⁵³, Zoran Gucev⁵⁴, Stephanie Dufek², Daniela Iancu², European dRTA consortium, Robert Kleta^{1,2}, Franz Schaefer³, Detlef Bockenhauer^{1,2}.

¹Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; ²Centre for Nephrology, University College London, UK ³Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany; ⁴Division of Nephrology, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy; ⁵Pediatric nephrology - CHU Arnaud de Villeneuve. Montpellier University Hospital - Montpellier - France; ⁶Ali-Asghar Clinical Research Development Center, Iran University of Medical Sciences, Tehran, Iran; ⁷Department of Pediatrics, University of Zielona Góra, Zielona Góra, Poland; ⁸Centre de référence maladies rénales rares, Bron, France; ⁹ASST Niguarda – Milan, Italy; ¹⁰Department of Pediatrics, University Hospital of Cologne, Cologne, Germany; ¹¹University Hospital Leuven, Belgium; ¹²King Edward Memorial Hospital, Pune, India; ¹³Department of Pediatrics, Center of Pediatric Nephrology & Transplantation, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt; ¹⁴Hospital Universitario Vall d'Hebron, Barcelona, Spain; ¹⁵Division of Pediatric Nephrology, NRS Medical College, Kolkata, India; ¹⁶Pediatric Nephrology, Dialysis and Transplant Unit- Az. Ospedaliera & University of Padova, Italy; ¹⁷University Children's Hospital, Medical School, Skopje, Macedonia; ¹⁸National Medical and Research Centre for Children's Health, Moscow; ¹⁹Centre Hospitalier Universitaire de Toulouse, Service de Néphrologie Pédiatrique, Hopital des Enfants, Centre De Reference des Maladies Rénale Rares du Sud Ouest, Toulouse, France; ²⁰Hospital Universitario Central de Asturias, Oviedo, Spain; ²¹Radboud University Medical Centre, Nijmegen, Netherlands; ²²Nephrology and Dialysis Unit,

Department of Woman, Child and Urological Diseases, Azienda Ospedaliero-Universitaria 'Sant'Orsola-Malpighi', Bologna, Italy; ²³*Charité Universitätsmedizin Berlin, Germany;* ²⁴*University Children's Hospital, Münster, Germany;* ²⁵*Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands;* ²⁶*Centro Hospitalar de Lisboa Central, Lisbon, Portugal;* ²⁷*4th Ped.Dep. Aristotle University, Thessaloniki, Greece;* ²⁸*Lady Cilento Children's Hospital, Brisbane, Australia;* ²⁹*School of Medicine, The University of Queensland, Brisbane, Australia;* ³⁰*Department of Pediatric Nephrology, Pamukkale University School of Medicine, Denizli, Turkey;* ³¹*Nephrology Unit Azienda Ospedaliera Papa Giovanni XXIII Bergamo, Italy;* ³²*Karolinska Institutet and Lund University, Sweden;* ³³*Group Florence Nightingale Hospitals, İstanbul, Turkey;* ³⁴*Fondazione Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy;* ³⁵*Pediatric Nephrology Center of Excellence and Pediatric Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia;* ³⁶*Pediatric Nephrology, Dialysis and Transplant Unit. Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy;* ³⁷*Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples, Italy;* ³⁸*Pediatric Department, Lillebaelt Hospital Kolding, Denmark;* ³⁹*Haseki Education and Research Hospital, İstanbul, Turkey;* ⁴⁰*Belarusian State Medical University, Minsk, Belarus;* ⁴¹*Department of Genetics, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France;* ⁴²*Pediatric Nephrology Unit, AOU Policlinic G Martino, Messina, Italy;* ⁴³*Necker hospital, Paris, France;* ⁴⁴*Erciyes University, Faculty of medicine, Department of Pediatric Nephrology, Kayseri, Turkey;* ⁴⁵*Cukurova University, Adana, Turkey;* ⁴⁶*Vilnius university, Santaros klinikos, Vilnius, Lithuania;* ⁴⁷*University Hospital of Lille, France;* ⁴⁸*Department of Renal Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia;* ⁴⁹*University Hospital Centre Zagreb, Croatia;* ⁵⁰*Department of Pediatrics, SMDZ in Zabrze, SUM in Katowice, Poland;* ⁵¹*Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany;* ⁵²*Department of Pediatrics, Seoul University Children's Hospital, Seoul, Korea;* ⁵³*Institute of Child Health, Kolkata, India;* ⁵⁴*University Children's Hospital, Medical School, Skopje, Macedonia.*

The European dRTA consortium consists of the authors, as well as:

Amira Peco-Antić⁵⁵, Amrit Kaur⁵⁶, Antonino Paglialunga⁵⁷, Aude Servais⁵⁸, Branko Lutovac⁵⁹, Ewout J. Hoorn⁶⁰, Hadas Shasha-Lavsky⁶¹, Jerome Harambat⁶², Astrid Godron-Dubrasquet⁶², Kathrin Budner⁶³, Lise Allard⁶⁴, Ludwig Patzer⁶⁵, Marina Shumikhina⁶⁶, Matthias Hansen⁶⁷, Nikoleta Printza⁶⁸, Nuran Küçük⁶⁹, Ortraud Beringer⁷⁰, Rajendra Bhimma⁷¹, Rimante Cerkauskiene^{72,73}, Thomas J Neuhaus⁷⁴, Valbona Stavileci⁷⁵, Tim Ulinski⁷⁶, Nida Temizkan Dincel⁷⁷, Nilufar Mohebbi⁷⁸.

⁵⁵Department of Nephrology, University Children's Hospital, Belgrade, Serbia; ⁵⁶Department of Paediatric Nephrology, Royal Manchester Children's Hospital, UK; ⁵⁷ASP de Ragusa, Modica, Italy; ⁵⁸Department of Nephrology, Centre Hospitalier Universitaire Necker, APHP, Paris, France; ⁵⁹Clinical Centre of Montenegro, Institute for Children's Disease, Podgorica, Montenegro; ⁶⁰Erasmus Medical Center, Rotterdam, Netherlands; ⁶¹Galilee Medical Center, Nahariya, Israel; ⁶²Pediatric Nephrology Unit, Bordeaux University Hospital, France; ⁶³Pediatric Department. University Hospital Carl Gustav Carus Dresden, Germany; ⁶⁴Department of Pediatrics, Angers University Hospital, Angers, France; ⁶⁵Children's Hospital St. Elisabeth and St. Barbara, Halle, Germany; ⁶⁶Filatov Children's Clinical Hospital №13, Moscow, Russia; ⁶⁷KfH Centre of Paediatric Nephrology, Clementine Children's Hospital, Frankfurt, Germany; ⁶⁸1st Pediatric Department, Aristotle University, Thessaloniki, Greece; ⁶⁹Kartal Dr.Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey; ⁷⁰University Children's Hospital, Ulm, Germany; ⁷¹Inkosi Albert Luthuli Central Hospital , Durban, South Africa; ⁷²Vilnius University, Faculty of medicine Children's hospital, Lithuania; ⁷³Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania; ⁷⁴Children's Hospital of Lucerne, Cantonal Hospital of Lucerne, Switzerland; ⁷⁵Pediatric Clinic, Prishtina, Kosovo; ; ⁷⁶Pediatric Nephrology Department, Armand Trousseau University Hospital, APHP, Paris, France; ⁷⁷Health Sciences University, Izmir Dr Behcet Uz Children Hospital, Turkey; ⁷⁸Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.

Corresponding author:

Prof. Dr. D. Bockenhauer

Department of Pediatric Nephrology

Great Ormond Street Hospital NHS Trust

Great Ormond Street

London WC1N 3JH

Tel: +44 20 7405 9200

d.bockenhauer@ucl.ac.uk

Index

INDEX	4
SUPPLEMENTAL TABLES.....	5
SUPPLEMENTAL TABLE 1: DATA POINTS COLLECTED.....	5
SUPPLEMENTAL TABLE 2: VALID AND MISSING DATA.....	7
SUPPLEMENTAL TABLE 3. GROSS DOMESTIC PRODUCT (GDP) PER CAPITA IN THE PARTICIPATING COUNTRIES.	8
SUPPLEMENTAL TABLE 4. PARTICIPATING COUNTRIES.....	9
SUPPLEMENTAL TABLE 5. DATA SUMMARY OF THE WHOLE COHORT	10
SUPPLEMENTAL TABLE 6. TREATMENT FORMULARY.	20
SUPPLEMENTAL FIGURES.....	22
SUPPLEMENTAL FIGURE 1. SODIUM VERSUS POTASSIUM CONTAINING ALKALI SUPPLEMENTATION IN RELATION TO COUNTRIES GDP AND PRESENCE OF HYPERCALCIURIA.....	22
SUPPLEMENTAL FIGURE 2: CKD STRATIFICATION AND COMPARISON DRTA 2017 vs NHANES III	23
SUPPLEMENTAL FIGURE 3. AGE AT DIAGNOSE OF NEPHROCALCINOSIS.....	24
SUPPLEMENTAL FIGURE 4. AGE AT PRESENTATION AND PER CAPITA GDP.....	25

Supplemental Tables

Supplemental table 1: Data points collected

Supplemental Table 1. Data points collected		
Renal Unit details	Laboratory	
Treating physician	Serum creatinine ($\mu\text{mol/L}$)	
Email address	Serum bicarbonate (mmol/L)	
Centre – City	Urinary calcium/creatinine (mmol/mmol)	
Country	Treatment (mmols/day)	
ERK-Net centre (y/n)	Bicarbonate (sodium +/- potassium)	
Demographic data	Citrate (sodium +/- potassium)	
Patient ID	Others	
Gender (F/M)		
Age at presentation (years)	Comorbidities	
Genetic information	Nephrocalcinosis (y/n)	
Gene	Age at diagnosis (years)	
Mutation details	Urolithiasis (y/n)	
Auxiometry	Age lithiasis was first diagnosed (years)	
Current age (years)	Hearing loss (y/n)	
Current height (cm)	Hearing aids prescribed (y/n)	
Current weight (kg)	Age at prescription (years)	
	Cochlear implantation (y/n)	
	Age when implanted (years)	

Shown are the data points that were requested in the online form.

Physicians were invited to participate via the following email:

Dear colleagues,

We, the working groups for inherited kidney diseases of ERA-EDTA and ESPN and ERKNet, are aiming at better understanding the long-term outcome of patients with dRTA, as well as current treatment practices. To this end, we would be grateful if you could fill in our brief online survey for each of your patients with a presumed or proven inherited form of dRTA.

To enter the survey, please copy the following Web link to your browser:

<https://www.surveymonkey.de/r/drta>

With the patient file at hand, it should not take more than 5 minutes per patient to complete the survey.

If more than one colleagues from a center respond to this survey, please make sure to enter each patient only once.

The survey should work equally well from a PC, iPad and Smartphone.

We aim to publish the results and physicians contributing to this survey will be sharing into the authorship; either as named members of the "European dRTA consortium" or, if you contribute three or more patients, as named co-authors.

We greatly appreciate your help!

Detlef Bockenhauer and Franz Schaefer

Supplemental table 2: Valid and missing data

Supplemental Table 2. Variables Valid and Missing data	N	
	Valid	Missing
Gender	340	0
Age at presentation	336	4
Current age	340	0
Mutation	340	0
Current weight	334	6
Height SDS	323	17
Alkali daily dose	334	6
Serum Creatinine ($\mu\text{mol/L}$)	340	0
Serum bicarbonate	340	0
Treatment option	340	0
Hypercalciuria	312	28
Nephrocalcinosis	339	1
Age at diagnosis of Nephrocalcinosis (N=299)	261	38
Nephrolithiasis	331	9
Age at diagnosis of Nephrolithiasis (N=79)	64	15
Hearing loss	326	14
Hearing aids	90	0
Age when aids were prescribed	76	14
Cochlear Implants	24	2
Age at cochlear implantation	22	2

Shown are the numbers of patients for whom the requested data were available ("valid") or not ("missing")

Supplemental Table 3. Gross Domestic Product (GDP) per capita in the participating countries.

Participating countries were classified in three different groups according to their per capita GDP in 2016 as “Low” (<10.000 USD/year), “Medium” (10.000-35.000 USD/year) or “High” (>35.000 USD/year).

Supplemental Table 3. Gross Domestic Product (GDP) per capita in the year 2016		
Country Name	GDP per capita (current US\$)	GPD (low/medium/high)
India	1709.59	LOW
Egypt, Arab Rep.	3477.85	LOW
Kosovo	3661.43	LOW
Belarus	4989.43	LOW
Iran, Islamic Rep.	5219.11	LOW
Macedonia, FYR	5237.15	LOW
South Africa	5274.55	LOW
Serbia	5426.20	LOW
Montenegro	7028.93	LOW
Russian Federation	8748.37	LOW
Turkey	10862.60	MEDIUM
Croatia	12149.19	MEDIUM
Poland	12414.10	MEDIUM
Lithuania	14912.69	MEDIUM
Greece	17890.57	MEDIUM
Portugal	19871.72	MEDIUM
Saudi Arabia	20028.65	MEDIUM
Spain	26616.49	MEDIUM
Italy	30668.98	MEDIUM
France	36857.12	HIGH
Israel	37180.53	HIGH
United Kingdom	40412.03	HIGH
Belgium	41271.48	HIGH
Germany	42161.32	HIGH
Netherlands	45637.89	HIGH
Australia	49755.32	HIGH
Sweden	51844.76	HIGH
Denmark	53578.76	HIGH
Switzerland	79887.52	HIGH

Supplemental Table 4. Participating countries.

Supplemental table 4: response rate according to country of the submitting clinician

Shown is the number of patients according to submitting country

Table 1. Participating countries.			
Country	Patients Included	Country	Patients Included
Italy	59	Greece	6
France	39	Lithuania	5
Germany	36	Portugal	5
UK	33	Denmark	4
Turkey	23	Saudi Arabia	4
India	22	Sweden	4
Poland	12	Belarus	3
Spain	12	Croatia	3
Netherlands	10	Switzerland	2
Iran	9	Israel	1
Australia	8	Kosovo	1
Egypt	7	Montenegro	1
Macedonia	7	Serbia	1
Russia	7	South Africa	1
Belgium	6		

Supplemental Table 5. Data summary of the whole cohort

Genetic results included when available. N.M.I.: No pathogenic mutation identified, AR: Autosomal Recessive, AD: Autosomal Dominant, H: homozygous, h: heterozygous, ch: compound heterozygous Mutation details as reported by the submitting clinicians. No formal genetic report was submitted and some results may have been obtained on a research basis only, without confirmation by a clinical genetic laboratory. Thus, genetic data need to be interpreted with caution. In some patients, clinicians had only noted the underlying gene, but were unable to retrieve the exact mutation details ("exact genotype not retrievable"). "Uca/Ucr normalised" refers to ratio of the concentrations of calcium and creatinine in the urine, normalised to the upper limit of normal of the age-appropriate reference range. Thus, a value >1.0 reflects hypercalciuria. The columns "Hearing aids (years)" and "cochlear implants (years)" detail the age at which this was prescribed or performed.

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow Up	(ml/ min)	Stages I-V	HCO ₃ ⁻ (mmol/L)	Hyper- Treatment		Metabolic		Nephro-		Hearing		Hearing prescription (age)	Cochlear Implantation (years)	Cochlear Implantation Time (years)
										Creatinine (mEq/ μmol/L)	kg/day)	Follow Up	eGFR	CKD Stages	HCO ₃ ⁻ (mmol/L)	Treatment	Hyper- calciuria	Metabolic Control	Nephro- calcinosi	Nephro- lithiasis	Hearing loss	Hearing aids						
Female	0.2	ATP6V0A4	AR	H	c.[823A>C]+ c.[823A>C] c.[2257C>T]+ c.[639+1G>A]+ c.[16C>T]+ c.[16C>T] c.[2035G>T]+ c.[2035G>T] c.[2257+1G>A]+	p.[Thr275Pro]+ p.[Thr275Pro] p.[Gln753*]+ p.[Gln753*] p[?]+p[?] p.[Arg6*]+ p.[Arg6*] p.[Asp679Tyr]+ p.[Asp679Tyr] p.[?]+p.[?]	5.6	61.5	1.58	17.7	2.1	0.2	127	CKD-1	22.5	Both	No	Yes	Yes	No	No	No	No	No	No	0.0		
Male	0.2	ATP6V0A4	AR	H	c.[2257C>T] c.[639+1G>A]+ c.[?]+p[?]	7.7	71	-0.98	17.7	3.9	0.9	146	CKD-1	22.6	Both	No	Yes	Yes	No	No	No	No	No	No	0.7			
Female	0.16	ATP6V0A4	AR	H	c.[639+1G>A] c.[16C>T]+ c.[2035G>T]+ c.[2035G>T] c.[2257+1G>A]+	7.7	70.5	-3.2	24	2.5	1.5	107	CKD-1	20	HCO3	No	No	Yes	No	No	No	No	No	No	1.3			
Male	0.2	ATP6V0A4	AR	H	c.[2035G>T]+ c.[2035G>T] c.[?]+p[?]	10	83	-1.32	26	3.4	2	117	CKD-1	20	Citrate	No	No	Yes	No	No	No	No	No	No	1.8			
Female	0.9	ATP6V0A4	AR	H	c.[2257+1G>A]+ c.[2257C>T]+ c.[2308C>T]+ c.[?]+p[?]	11.3	84	-0.62	49	2.7	2	63	CKD-2	27.2	HCO3	Yes	No	Yes	No	No	No	No	No	No	1.1			
Male	0.1	ATP6V0A4	AR	H	c.[2257+1G>A] c.[2257C>T]+ c.[?]+p[?]	13.6	91.3	0.94	34	4.7	2	98	CKD-1	20	Citrate	Yes	No	Yes	No	No	No	No	No	No	1.9			
Male	0.25	ATP6V0A4	AR	H	c.[2257C>T] c.[?]+p[?]	9.6	83	-1.32	31	5	2	98	CKD-1	18.7	Both	No	No	Yes	No	No	No	No	No	No	1.8			
Female	0	ATP6V0A4	AR	CH	c.[2257C>T] c.[639+1G>A]+ c.[?]+p[?]	14	93.7	2.22	29	5.4	2	118	CKD-1	24	Citrate	No	Yes	Yes	No	No	No	No	No	No	2.0			
Female	0.08	ATP6V0A4	AR	H	c.[639+1G>A] c.[596T>A]+ c.[?]+p[?]	11.5	87	0.23	24	5.9	2	132	CKD-1	22	Both	No	Yes	Yes	No	No	No	No	No	No	1.9			
Male	1.1	ATP6V0A4	AR	H	c.[596T>A] c.[1107delC]+ c.[?]+p[?]	11.5	74	-4.12	40	9.1	2.2	67.5	CKD-2	22	Citrate	Yes	No	Yes	Yes	No	No	No	No	No	1.1			
Female	0.1	ATP6V0A4	AR	H	c.[1107delC] c.[1185delC]+ c.[?]+p[?]	12.8	89	-1.33	21	1.9	3	155	CKD-1	22	Citrate	Yes	No	Yes	No	No	No	No	No	No	2.9			
Male	2.3	ATP6V0A4	AR	H	c.[1185delC] c.[162_169 dup]+ c.[?]+p[?]	11.8	86	-2.58	22	3.2	3	143	CKD-1	19	Both	No	No	Yes	No	No	No	No	No	No	0.7			
Male	0	ATP6V0A4	AR	H	c.[162_169 dup] c.[2227C>T]+ c.[?]+p[?]	13.9	95.5	0.19	35	3.2	3	100	CKD-1	26	Citrate	No	Yes	Yes	No	No	No	No	No	No	3.0			
Male	0.1	ATP6V0A4	AR	H	c.[2227C>T] c.[1181-1185del]+ c.[?]+p[?]	12.2	91	-1.14	30.9	2.3	3	107	CKD-1	25.6	Citrate			Yes	No	No	No	No	No	No	2.9			
Male	0.3	ATP6V0A4	AR	H	c.[1181-1185del] c.[596T>A]+ c.[?]+p[?]	16.2	89.3	-2.56	22	2.5	3.5	148	CKD-1	11.6	Citrate	No	No	Yes	Yes	Yes	Yes	Yes	1 Yes	1.6	3.2			
Male	0.83	ATP6V0A4	AR	H	c.[596T>A] c.[1107delC]+ c.[?]+p[?]	13	92	-2.04	46	9.2	3.7	73.1	CKD-2	22	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	1.4 No	2.9				
Male	0.2	ATP6V0A4	AR	H	c.[1107delC] c.[1691+2dupT]+ c.[?]+p[?]	14	97.4	-1.31	27	6.9	4	132	CKD-1	26	Citrate	No	Yes	Yes	No	No	No	No	No	No	3.8			
Female	0.16	ATP6V0A4	AR	CH	c.[2293_2294insA] exact genotype not retrievable	14.6	99	-0.47	33	3.3	4	110	CKD-1	20	HCO3	No	No	Yes	No	No	No	No	No	No	3.8			
Female	0	ATP6V0A4	AR	H	c.[1185delC]+ c.[?]+p[?]	16.1	110.6	0.63	34	3.4	5	119	CKD-1	22.8	Citrate	No	Yes	Yes	No	No	No	No	No	No	5.0			
Female	0.4	ATP6V0A4	AR	CH	c.[1691+2dupT] c.[387C>A]+ c.[?]+p[?]	16.5	109	-0.15	34	6.7	5.3	117	CKD-1	24	Both	Yes	No	Yes	Yes	No	No	No	No	No	4.9			
Female	0.16	ATP6V0A4	AR	CH	c.[2257C>T] c.[1185delC]+ c.[?]+p[?]	18.2	112	-0.59	30	2.7	6	136	CKD-1	24	Citrate	Yes	No	Yes	No	Yes	Yes	Yes	3.5 No	5.8				
Female	0.2	ATP6V0A4	AR	CH	c.[1345C>T] c.[1955C>G]+ c.[?]+p[?]	18.4	109	-1.2	60	3.1	6	66	CKD-2	27	Both	No	Yes	Yes	No	Yes	No	No	No	No	5.8			
Male	0.4	ATP6V0A4	AR	H	c.[1955C>G] c.[1029+1G>A]+ c.[?]+p[?]	18.5	112	-0.82	32	16.2	6.11	127.8	CKD-1	20	Citrate	No	No	Yes	No	No	No	No	No	No	5.7			
Male	0	ATP6V0A4	AR	CH	c.[1345C>T] c.[1345C>T]+ c.[?]+p[?]	27.5	129	0.15	55	1.5	8	86	CKD-2	20.1	Both	Yes	No	Yes	No	No	No	No	No	No	8.0			
Female	0.2	ATP6V0A4	AR	H	c.[1345C>T] c.[417_429del]+ c.[?]+p[?]	38.5	138.2	0.77	43	0.8	9	117	CKD-1	29	Citrate	No	Yes	Yes	No	No	No	No	No	No	8.8			
Male	0.08	ATP6V0A4	AR	CH	c.[1920_1921delAA] c.[752_755del]+ c.[?]+p[?]	32.8	134.2	-0.74	56	2.5	10	87	CKD-2	23.1	Citrate	No	Yes	Yes	No	No	No	No	No	No	9.9			
Female	0	ATP6V0A4	AR	H	c.[752_755del] c.[828_831del]+ c.[?]+p[?]	39.4	142.5	0.7	47	1.4	10	111	CKD-1	23.4	HCO3	No	Yes	Yes	No	No	No	No	No	No	10.0			
Female	0.08	ATP6V0A4	AR	H	c.[828_831del] c.[?]+p[?]	27.2	130.3	-1.25																				

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow Up		HCO ₃ ⁻ (mmol/L)	Hyper- Treatment	Metabolic calciuria Control	Nephro- calcinosi s	Nephro- lithiasis	Hearing loss		Hearing prescription (age)	Cochlear Implantation	Cochlear Implantation (years)	Time of FU (years)	
										Creatinine (mEq/ μmol/L)	Follow kg/day	eGFR ml/min	Stages	I-V													
Female	0	ATP6V0A4	AR	CH	c.[367G>T]+ c.[387C>A]	p.[Glu123*]+ p.[Tyr129*]	37	139	-0.73	44	0.9	11	115	CKD-1	20	Both	No	No	Yes	Yes	No	No	No	No	No	11.0	
Female	0	ATP6V0A4	AR	H	exact genotype not retrievable		30.5	148	0.51	50.3	2	11	107	CKD-1	26.6	Citrate	No	Yes	Yes	No	No	No	No	No	No	11.0	
Male	0.1	ATP6V0A4	AR	H	c.[1312_1315del]+ c.[1312_1315del]	p.[Asp438Metfs*13]+ p.[Asp438Metfs*13]	32.7	145.6	-0.45	57	4.6	12	93	CKD-1	28	Citrate	No	Yes	Yes	No	No	No	No	No	No	11.9	
Female	0.1	ATP6V0A4	AR	H	c.[1030_2A>C]+ c.[1030_2A>C]	p.?:+p.?:	42	149	-0.8	35	5.2	12.5	155	CKD-1	22.2	Both	No	Yes	Yes	No	No	No	No	No	No	12.4	
Female	0.2	ATP6V0A4	AR	H	c.[1908+1G>T]+ c.[1908+1G>T]	p.?:+p.?:	31	140	-2.48	52.2	1.5	13	98	CKD-1	25	Citrate			Yes	No	No	No	No	No	No	No	12.8
Female	0.5	ATP6V0A4	AR	CH	c.[2257C>T]	p.[Gln753*]	45.5	158	-0.38	43	1.2	14	134	CKD-1	26	Citrate	No	Yes	Yes	No	Yes	Yes	2.8	Yes	10.8	13.5	
Male	0	ATP6V0A4	AR	H	c.[752_755del]+ c.[752_755del]	p.[Glu251Valfs*14]+ p.[Glu251Valfs*14]	46.5	154.6	-1.12	68	1.6	14	83	CKD-2	19.3	HCO3	No	No	Yes	No	No	No	No	No	No	14.0	
Female	2.5	ATP6V0A4	AR	H	c.[322C>T]+ c.[25_27del]+	p.[Gln108*] p.[Glu9del]+	61	164.5	0.56	49	0.7	14.5	123	CKD-1	23	HCO3	No	Yes	Yes	No	Yes	Yes	12.5	Yes	13	12.0	
Male	0	ATP6V0A4	AR	CH	c.[863C>A]	p.[Ala288Asp]	62	173	0.37	68	1	15	93	CKD-1	28	Citrate	No	Yes	Yes	No	No	No	No	No	No	15.0	
Male	0.5	ATP6V0A4	AR	CH	c.[1478+1G>A]+ c.[2190C>G]	p.[Tyr730*] p.?:+p.?:	64.4	174	0.36	68	0.9	15.3	93	CKD-1	23.8	Both	No	Yes	Yes	No	No	No	No	No	No	14.8	
Male	0.1	ATP6V0A4	AR	H	c.[1691+1G>A]	p.[Arg6*]+	60.6	174.4	0.05	93	2.5	16	68	CKD-2	26	HCO3	No	Yes	Yes	No	No	No	No	No	No	15.9	
Male	0.3	ATP6V0A4	AR	CH	c.[970delG]	p.[Glu324Argfs*22]	69.6	180.2	0.87	93	1	16	71	CKD-2	27	HCO3	No	Yes	Yes	No	No	No	No	No	No	15.7	
Female	0.1	ATP6V0A4	AR	H	c.[188_189del]+ c.[188_189del]	p.[Arg63Asnfs*12]+ p.[Arg63Asnfs*12]	46.5	155	-1.17	63	2.3	16	90	CKD-1	24	HCO3	No	Yes	Yes	No	Yes	Yes	14	No	15.9		
Female	0	ATP6V0A4	AR	CH	c.[367G>T]+ c.[387C>A]	p.[Glu123*] p.[Tyr129*]	54	169	0.99	44	1.8	16	140	CKD-1	25	Both	No	Yes	Yes	No	Yes	Yes	12	No	16.0		
Male	1	ATP6V0A4	AR	H	c.[1920_1921delAA]+ c.[1920_1921delAA]	p.[Ser641Phefs*17]+ p.[Ser641Phefs*17]	80	166	-1.26	127	1.1	17	48	CKD-3	20.8	HCO3	No	No	Yes	No	No	No	No	No	No	16.0	
Male	0	ATP6V0A4	AR	CH	c.[25_27del]+ c.[863C>A]	p.[Glu9del]+ p.[Ala288Asp]	82	187	1.64	88	0.7	17	78	CKD-2	32	Citrate	No	Yes	Yes	No	No	No	No	No	No	17.0	
Male	0.1	ATP6V0A4	AR	H	1G>A]	p.?:+p.?:	41.5	148.2	-3.55	226	1.7	17	24	CKD-4	21	HCO3	Yes	No	No	No	No	No	No	No	No	16.9	
Male	0.1	ATP6V0A4	AR	H	c.[1345C>T]+ c.[1345C>T]	p.[Arg449Cys]+ p.[Arg449Cys]	67.5	158	-2.36	72	2.4	17.3	80	CKD-2	22.2	Both	No	Yes	Yes	No	No	No	No	No	No	17.2	
Male	0.25	ATP6V0A4	AR	CH	c.[2257C>T]	p.[Gln753*]	42	160	-2.22	50	1.3	18	116.8	CKD-1	24	Citrate	No	Yes	Yes	No	No	No	No	No	No	17.8	
Female	0.3	ATP6V0A4	AR	CH	c.[1572G>A]	p.[Pro524=]	60.4	165	0.26	73	2	23	85.7	CKD-2	17.4	Both	No	No	Yes	No	No	No	No	No	No	22.7	
Female	0.25	ATP6V0A4	AR	CH	c.[414_417+10del14]+ c.[1571 C>T]	p.?:+ p.[Pro524leu] p.[Glu713Serfs*50]+	60	159	-0.67	86.6	1.2	27	68.1	CKD-2	15.9	Both	No	No	Yes	Yes	Yes	Yes	No	No	26.8		
Female	0.08	ATP6V0A4	AR	H	c.[2137delG]+ c.[2137delG]	p.[Glu713Serfs*50]+ p.[Glu713Serfs*50]	62.4	162	-0.21	48	1.7	28	133.6	CKD-1	19	Both	No	No	Yes	Yes	Yes	Yes	7	No	27.9		
Female	0.08	ATP6V0A4	AR	H	c.[322C>T]+ c.[322C>T]	p.[Gln108*]+ p.[Gln108*]	59.7	151	-1.9	61	1.5	29	100.6	CKD-1	24	HCO3	No	Yes	Yes	No	Yes	Yes	4	No	28.9		
Female	2	ATP6V0A4	AR	H	c.[1345>T]+ c.[1345>T]	p.[Arg449Cys]+ p.[Arg449Cys]	47	160	-0.52	148	1	32	35.5	CKD-3	17.8	Citrate			Yes	Yes	Yes	No	No	No	30.0		
Female	0.6	ATP6V0A4	AR	H	c.[1345>T]	p.[Arg449Cys]	54	158	-0.82	105	1.7	32	52.7	CKD-3	16.5	Citrate	No	No	Yes	No	Yes	Yes	4	No	31.4		
Female	0.1	ATP6V0A4	AR	H	c.[2426A>C]+ c.[2426A>C]	p.[Hys809Arg]+ p.[Hys809Arg]	68	162	-0.21	61.9	1.3	35	95.2	CKD-1	22.6	Both	No	Yes	Yes	Yes	Yes	Yes	No	No	34.9		
Male	0.08	ATP6V0A4	AR	H	c.[417+1G>A]+ c.[196+4A>G]+	p.?:+p.?:	61.8	160.5	-0.3	124	0.8	38	56.6	CKD-3	24.5	HCO3	No	Yes	Yes	No	Yes	Yes	No	No	37.9		
Female	0.25	ATP6V0A4	AR	H	c.[196+4A>G]+ c.[2215G>C]	p.?:+p.?:	73	165	0.26	74.3	0.7	39	75.4	CKD-2	17.4	Both			Yes	Yes	Yes</td						

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow Up		HCO ₃ ⁻ (mmol/L)	Hyper- Treatment	Hearing Nephro- calcinosis		Hearing Nephro- lithiasis		Hearing prescription aids		Cochlear Implantation		Cochlear Implantation prescription of FU (years)	
										Creatinine (mEq/ μmol/L)	Follow kg/day	eGFR ml/min	Stages	I-V													
Female	0	ATP6V0A4	AR	H	c.[752_755del]+ c.[752_755del] c.[40C>T]+ c.[816+1G>A]+	p.[Glu251Valfs*14]+ p.[Glu251Valfs*14] p.[Gln14*]+ p.[?]+ p.[Pro631Ser]	54.6	156.1	-1.13	68	1.7	39	83.6	CKD-2	30.5	HCO3	No	Yes	Yes	Yes	No	No	No	No	39.0		
Male	0.08	ATP6V0A4	AR	CH	c.[1891C>T] c.[1185delC]+	p.[Tyr396Thrfs*12]+	52	169	0.89	97	1.2	40	74.4	CKD-2	29	HCO3	No	Yes	Yes	No	Yes	Yes	Yes	20	No	39.9	
Female	0.1	ATP6V0A4	AR	CH	c.[1754_1781dup28] c.[1356del]+	p.[Ile594Metfs*18] p.[Phe452fsX35]+	54	146	-2.66	90	1.5	43	59.3	CKD-3	23.8	Both	No	Yes	Yes	Yes	Yes	Yes	Yes	39	No	42.9	
Male	0	ATP6V1B1	AR	H	c.[1356del] c.[91C>T]+	p.[Phe452fsX35] p.[Arg31*]+	6.9	65	-1.15	17.7	3.6	0.5	134	CKD-1	25	Citrate	No	Yes	Yes	No	Yes	No	No	No	0.5		
Female	0	ATP6V1B1	AR	CH	c.[1155dupIC] c.[175-1G>C]+	p.[Ile386Hisfs*56] p.[?]+	5.6	66	-0.05	16	1.8	0.5	151	CKD-1	22	Citrate	No	Yes	Yes	No	No	No	No	No	0.5		
Female	1.4	ATP6V1B1	AR	CH	c.[1155dupIC] c.[91C>T]+	p.[Ile386Hisfs*56] p.[Arg31*]+	11.3	83.5	-1.3	32	1.4	2.4	95	CKD-1	18.1	HCO3	No	No	Yes	No	Yes	Yes	Yes	1.9	No	1.0	
Female	1.2	ATP6V1B1	AR	H	c.[91C>T] c.[175-1G>C]+	p.[Arg31*] p.[?]+	9.5	70	-5.52	36	9.5	2.5	71.0	CKD-2	20	Citrate	Yes	No	Yes	No	Yes	Yes	Yes	1.2	No	1.3	
Female	2.5	ATP6V1B1	AR	CH	c.[1155dupIC] c.[232G>A]+	p.[Ile386Hisfs*56] p.[Gly78Arg]+	15.7	94	-0.89	44	2.4	3.5	78	CKD-2	16.3	Both	No	No	Yes	No	Yes	No	No	No	1.0		
Female	2	ATP6V1B1	AR	CH	c.[988G>C] c.[1387G>T]+	p.[Glu330Gln] p.[Glu463*]+	13.8	92.3	-1.38	35	1.1	3.5	96	CKD-1	18	HCO3	No	No	Yes	No	Yes	Yes	Yes	0.5	No	1.5	
Female	0.3	ATP6V1B1	AR	H	c.[1387G>T] c.[242T>C]+	p.[Glu463*] p.[Leu81Pro]+	19.2	98.2	-0.7	25	0.9	4	143	CKD-1	21	Citrate	No	No	Yes	No	Yes	No	No	No	3.7		
Female	2	ATP6V1B1	AR	H	c.[242T>C] c.[91C>T]+	p.[Leu81Pro] p.[Arg31*]+	20.5	100	-0.24	35.4	1.7	4	103	CKD-1	25	Both	No	Yes	Yes	No	No	No	No	No	2.0		
Female	0.5	ATP6V1B1	AR	H	c.[91C>T] c.[1037C>G]+	p.[Arg31*] p.[Pro346Arg]+	18	105	0.89	30.9	2	4	124	CKD-1	22.3	Citrate	Yes	No	Yes	No	Yes	Yes	1	No	3.5		
Male	0.3	ATP6V1B1	AR	H	c.[1037C>G] c.[242T>C]+	p.[Pro346Arg] p.[Leu81Pro]+	30.3	130.5	4.7	53	3	5	90	CKD-1	26	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	3	No	4.7	
Male	0.2	ATP6V1B1	AR	H	c.[242T>C] c.[242T>C]+	p.[Leu81Pro] p.[Leu81Pro]+	16	103	-1.32	35	2.8	5	107	CKD-1	24.9	Both	No	Yes	Yes	No	Yes	Yes	2.5	No	4.8		
Male	0.4	ATP6V1B1	AR	CH	c.[332del] c.[1148_1149insC]+	p.[Asp111Alafs*53] p.[Ile386Hisfs*56]+	24	110	0.18	45	2.3	5	89	CKD-2	22.3	Both	No	Yes	Yes	No	No	No	No	No	4.6		
Female	0.5	ATP6V1B1	AR	H	c.[1148_1149insC] c.[1249-3C>G]+	p.[Ile386Hisfs*56] p.[?]+p.[?]	16.5	105.6	-1.37	39	4.2	5.7	99	CKD-1	17	Both	No	No	Yes	No	Yes	Yes	2.5	Yes	4.9	5.2	
Male		ATP6V1B1	AR	H	c.[1249-3C>G] c.[1148_1149insC]+	p.[Ile386Hisfs*56]+	25.8	116	0.39	30	1.9	5.8	141	CKD-1	22	Both	No	Yes	No	Yes	No	No	No	No	No		
Male	2.5	ATP6V1B1	AR	H	c.[1148_1149insC] c.[91C>T]+	p.[Ile386Hisfs*56] p.[Arg31*]+	16.9	106.8	-1.71	25	1.9	6	156	CKD-1	25	Both	No	Yes	Yes	No	Yes	Yes	2.5	Yes	5	3.5	
Female	0	ATP6V1B1	AR	H	c.[91C>T] c.[1155dupC]+	p.[Arg31*] p.[Ile386Hisfs*56]+	21	114.4	-0.2	32	1	6	130	CKD-1	24.2	Citrate	No	Yes	Yes	No	Yes	No	Yes	Yes	0.7	6.0	
Female	0	ATP6V1B1	AR	H	c.[1155dupC] c.[1155dupC]+	p.[Ile386Hisfs*56] p.[Ile386Hisfs*56]+	30.5	122	0.55	35	1	6.6	127	CKD-1	22	Both	No	Yes	Yes	No	Yes	Yes	Yes	Yes	5.8	6.6	
Male	0.6	ATP6V1B1	AR	H	c.[1155dupC] c.[1156_1157insC]+	p.[Ile386Hisfs*56] p.[Ile386Thrfs*56]+	23	119.8	-0.38	43	2.1	7	102	CKD-1	26	HCO3	No	Yes	No	Yes	Yes	Yes	Yes	Yes	6.4		
Male	0.3	ATP6V1B1	AR	CH	c.[1354delT] c.[1249-3C>G]+	p.[Phe452Leufs*35] p.[?]+[?]	26	124	0.36	26.5	2.1	7	171	CKD-1	26	Citrate	No	Yes	Yes	No	Yes	Yes	1	No	6.7		
Male	0.6	ATP6V1B1	AR	H	c.[1249-3C>G] c.[340C>T]+	p.[Arg114*]+p.[?]	23	124	0.36	34	1.7	7	133	CKD-1	25	HCO3	No	Yes	Yes	No	No	No	No	No	6.4		
Female	1	ATP6V1B1	AR	CH	c.[785+1G>A] c.[815C>G]+	p.[Arg272Gly]+ p.[?]+[?]	24.3	126.5	0.92	46	3.3	7	100	CKD-1	25	Citrate	No	Yes	Yes	No	Yes	Yes	2	No	6.0		
Male	0.16	ATP6V1B1	AR	CH	c.[1054A>C] c.[1037C>G]+	p.[Asp352Hys] p.[Pro346Arg]+	23.5	118	-0.75	90	0.3	7	48	CKD-3	26.5	Citrate	No	Yes	Yes	No	No	No	No	No	6.8		
Male	0.3	ATP6V1B1	AR	CH	c.[1397C>A] c.[490_499del]+	p.[Ser466*] p.[Ile164Alafs*8]+	39	135	1.74	40	2.6	7.5	123	CKD-1	23.8	Both	No	Yes	No	No	Yes	Yes	Yes	No	7.2		
Female	0.1	ATP6V1B1	AR	H	c.[490_499del] c.[242T>C]+	p.[Ile164Alafs*8] p.[Leu81Pro]+	28.6	130.3	-0.51	45	3.8</td																

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow (ml/ kg/day)		HCO ₃ ⁻ (mmol/L)	Hyper- Treatment	Hearing Nephro- calcinosis		Hearing Nephro- lithiasis		Hearing prescription aids (age)		Cochlear Implantation (years)		Cochlear Implantation Time of FU (years)		
										Creatinine (mEq/ μmol/L)	Up	10	106	CKD-1	22	HCO3	Yes	No	Yes	Yes	0 Yes	2	10.0					
										Follow Up	Stages	I-V	min															
Female	0	ATP6V1B1	AR	H	c.[242T>C]+ c.[242T>C] c.[1155dupC]+ c.[1155dupC]	p.[Leu81Pro]+ p.[Leu81Pro] p.[Ile386Hisfs*56]+ p.[Ile386Hisfs*56]	26	128	-1.56	44	2.3	10	106	CKD-1	22	HCO3												
Female	0	ATP6V1B1	AR	H	c.[1155dupC] c.[242T>C]+ c.[242T>C] c.[1155dupC]+	p.[Ile386Hisfs*56] p.[Leu81Pro]+ p.[Leu81Pro] p.[Ile386Hisfs*56]+	25	138	-0.86	35	1	11	144	CKD-1	21	Both	No	No	Yes	Yes	Yes	Yes	Yes	Yes	3 No	11.0		
Male	0.5	ATP6V1B1	AR	H	c.[1155dupC] c.[1155dupC]+ c.[1155dupC]+ c.[340C>T]+	p.[Ile386Hisfs*56]+ p.[Leu81Pro] p.[Leu81Pro] p.[Arg114*]+	35	140	-0.53	55	2.9	11	93	CKD-1	23	Both	No	Yes	Yes	No						10.5		
Male	0.1	ATP6V1B1	AR	H	c.[1155dupC] c.[340C>T]+ c.[91C>T]+ c.[91C>T]+	p.[Ile386Hisfs*56] p.[Arg114*]+ p.[Ile386Hisfs*56] p.[Arg31*]+	23	121	-3.69	53	3.7	11.5	83	CKD-2	16	Citrate	Yes	No	Yes	No	Yes	Yes	Yes	Yes	5 No	11.4		
Female	5	ATP6V1B1	AR	CH	c.[1155dupC] c.[1155dupC] c.[1155dupC] c.[135-1G>C]+ c.[135-	p.[Ile386Hisfs*56] p.[Ile386Hisfs*56] p.[Ile386Hisfs*56] p.[?]+p.[?]	44.5	151.5	0.56	57	1.2	11.5	97	CKD-1	18	Citrate	No	No	Yes	No	Yes	Yes	Yes	Yes	5 Yes	11.4	6.5	
Male	0.5	ATP6V1B1	AR	CH	c.[497delC] c.[1155dupC]+ c.[1155dupC]	p.[Thr166Argfs*9] p.[Ile386Hisfs*56]+ p.[Ile386Hisfs*56]	31.4	136	-1.83	41.5	1.9	12	120	CKD-1	22.7	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	Yes	2 No	11.5		
Male	0.5	ATP6V1B1	AR	H	c.[135-1G>C]+ c.[135-	p.[?]+p.[?]	26	127	-3.49	70.7	2.6	12.5	66	CKD-2	17	Citrate	No	No	Yes	No	Yes	Yes	Yes	Yes	6 No	12.0		
Male	0	ATP6V1B1	AR	H	1G>C] c.[905G>C]+ c.[1469C>T]	p.[Arg302Pro]+ p.[Pro490Leu]	48	156	-0.05	53	1.1	13	107	CKD-1	23	Citrate	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1 No	13.0		
Male	2	ATP6V1B1	AR	CH	exact genotype not retrievable	p.[Arg302Pro]+ p.[Pro490Leu]	60.4	151.6	-0.56	66	2	13	84	CKD-2	18	Citrate	Yes	No	Yes	No	Yes	No	No	No	No	11.0		
Male	0.5	ATP6V1B1	AR	H	c.[242T>C]+ c.[242T>C] c.[1155dupC]+ c.[1155dupC]	p.[Leu81Pro]+ p.[Leu81Pro] p.[Ile386Hisfs*56]+ p.[Ile386Hisfs*56]	48.7	152	-0.56	40.7	1.2	13	136	CKD-1	26	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	Yes	2 Yes	12	12.5	
Male	7.3	ATP6V1B1	AR	H	c.[242T>C] c.[1155dupC]+ c.[1155dupC]	p.[Leu81Pro] p.[Ile386Hisfs*56]+ p.[Ile386Hisfs*56]	49.9	157	-0.65	70.7	1.8	13.8	81	CKD-2	22.7	Both	No	Yes	Yes	No	Yes	Yes	Yes	Yes	10 No	6.5		
Male	2	ATP6V1B1	AR	H	c.[1155dupC] c.[1249-3C>G]+ c.[1249-3C>G]	p.[Ile386Hisfs*56] p.[?]+p.[?]	39.7	150.5	-1.72	62	0.4	14.2	89	CKD-2	22	Citrate	No	Yes	Yes		Yes	Yes	Yes	Yes	Yes	12.2		
Male		ATP6V1B1	AR	H	c.[1249-3C>G]	p.[Leu81Pro]+	60.4	159	-1.16	53	1.1	14.7	110	CKD-1	21	Both	No	No	No	No	Yes	No	No	No	No			
Male	3	ATP6V1B1	AR	H	c.[242T>C] c.[242T>C] c.[469T>C]+ c.[469T>C]	p.[Leu81Pro] p.[Leu81Pro] p.[Arg157Cys]+ p.[Arg157Cys]	71	166	-0.99	97	1.3	16	62	CKD-2	21	Both	No	No	Yes	No	Yes	No	No	No	No	13.0		
Male	0	ATP6V1B1	AR	H	c.[469T>C] c.[585+1G>A]+ c.[585+1G>A]	p.[Arg157Cys] p.[?]+p.[?]	52	163	-1.37	74	0.7	16	80	CKD-2	24	HCO3	No	Yes	Yes	No	No	No	No	No	No	16.0		
Male	0.08	ATP6V1B1	AR	H	c.[585+1G>A] c.[175-1G>C]+ c.[175-	p.[?]+p.[?]	37	145	-3.48	57	1.1	16	93	CKD-1	21	Citrate	No	No	Yes	Yes	Yes	Yes	Yes	Yes	6 Yes	23	15.9	
Female	6	ATP6V1B1	AR	H	1G>C] c.[91C>T]+ c.[497delC]	p.[?]+p.[?]	52	170.5	1.28	62	1.2	16.3	100	CKD-1	17	Both	No	No	Yes	Yes	Yes	Yes	Yes	Yes	4 Yes	16.6	10.3	
Male	0.5	ATP6V1B1	AR	CH	c.[1037C>G]+ c.[1037C>G]	p.[Thr166Argfs*9] p.[Pro346Arg]+	51.9	152	-2.89	85.7	1.9	16.5	65	CKD-2	20.4	Citrate	Yes	No	Yes	No	Yes	Yes	Yes	Yes	3 No	16.0		
Male	0.1	ATP6V1B1	AR	H	c.[1037C>G]	p.[Pro346Arg]	71	168.2	-1.13	89.2	0.5	18	68.8	CKD-2	26	Both	No	Yes	No	Yes	Yes	Yes	Yes	Yes	3 Yes	16	17.9	
Female	0.11	ATP6V1B1	AR	H	c.[1155dupC] c.[242T>C]+ c.[242T>C]	p.[Ile386Hisfs*56] p.[Leu81Pro]+ p.[Leu81Pro]	47.5	166.8	0.6	77	2.9	18	79.1	CKD-2	24.1	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	Yes	1 No	17.9		
Male	4.5	ATP6V1B1	AR	H	c.[242T>C] c.[242T>C]	p.[Leu81Pro]	66.5	157	-2.62	136	1.7	18	42.1	CKD-3	16	Both	Yes	No	Yes	No	Yes	No	No	No	No	13.5		
Female	1	ATP6V1B1	AR	H	exact genotype not retrievable	p.[Pro346Arg]+	58.1	157.9	-0.79	60	0.6	18	96.1	CKD-1	25.6	HCO3	No	Yes	Yes	No	Yes	Yes	Yes	Yes	3.2 No	17.0		
Male	4	ATP6V1B1	AR	H	c.[1037C>G]	p.[Pro346Arg]	70	182	0.76	80	1	19	83	CKD-2	24.5	HCO3	No	Yes	Yes	No	Yes	No	No	No	No	15.0		
Female	0.16	ATP6V1B1	AR	H	c.[1155dupC]+ c.[1155dupC]	p.[Ile386Hisfs*56]+ p.[Ile386Hisfs*56]	45	156	-1.12	70.7	1.3	19	80.5	CKD-2	21	Citrate	Yes	No	Yes	No	Yes	No	No	No	No	No	18.8	
Male	0.4	ATP6V1B1	AR	CH	c.[1061G>A] c.[1418T>C]+ c.[1418T>C]	p.[Leu473Pro]+ p.[Leu473Pro]	60.5	163	-1.89	76	0.7	19	78.3	CKD-2	22	Citrate	No											

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow Up		HCO ₃ ⁻ (mmol/L)	Hyper- Treatment	Metabolic calciuria Control	Nephro- calcinosis	Nephro- lithiasis	Hearing loss		Hearing prescription (age)	Cochlear Implantation (years)	Cochlear Implantation prescription of FU (years)			
										Creatinine (mEq/ μmol/L)	kg/day)	Follow Up	eGFR (ml/ min)	Stages I-V	Hyper- calciuria Treatment	Metabolic Control	Nephro- calcinosis	Nephro- lithiasis	Hearing loss									
Male	1	ATP6V1B1	AR	H	c.[1155dupC]+	p.[Ile386Hisfs*56]+				c.[1155dupC]	p.[Ile386Hisfs*56]	65	174	-0.3	352.9	1.1	25	18.4	CKD-4	16.8 HCO3	No	No	No	Yes	No	No	24.0	
Female	2.5	ATP6V1B1	AR	CH	c.[539G>A]+	p.[Gly180Asp]+				c.[814G>C]	p.[Ala272Pro]	74	158	-0.82	91	1.9	28	63.8	CKD-2	21 Citrate	No	No	Yes	Yes	Yes	5 No	25.5	
Female	0.08	ATP6V1B1	AR	H	c.[1155dupC]	p.[Ile386Hisfs*56]+				c.[1155dupC]	p.[Ile386Hisfs*56]	69	152	-1.74	62	1.4	29	98.7	CKD-1	21 Both	No	No	Yes	No	Yes	6 No	28.9	
Female	0.08	ATP6V1B1	AR	H	c.[1155dupC]	p.[Ile386Hisfs*56]+				c.[585+1G>A]+	p.[Ile386Hisfs*56]	83	160	-0.52	69	1	35	84	CKD-2	19 Both	No	No	Yes	No	Yes	2 No	34.9	
Male	1.8	ATP6V1B1	AR	H	c.[585+1G>A]	p.[?]+p.?						69	164.5	0.27	91	0.5	40	80	CKD-2	26.7 HCO3	No	Yes	Yes	No	Yes	0 No	38.2	
Female	0.2	N.M.I.	No		Simple het: c.[785+1G>A]+[=]	p.[?]+[=]						6.7	65	-1.52	36	4.8	0.7	66	CKD-2	17.6 HCO3	No	No	No	No	No	No	0.5	
Female	0.5	N.M.I.	No	ATP6V1B1								9.2	72	-1.84	21	7.6	1.3	125	CKD-1	27 Both	No	Yes	Yes	No	No	No	0.8	
Female	1	N.M.I.	No		Simple het: c.[2035G>T]+[=]	p.[Asp679Tyr]+[=]						9.6	81	-0.77	25.6	2.8	1.8	115	CKD-1	23.8 Citrate	No	Yes	Yes	No	Yes	No	0.8	
Female	1	N.M.I.	No	ATP6VOA4								11.5	89	0.8	20.3	5.2	2	160	CKD-1	22.1 HCO3	No	Yes	Yes	No	No	No	1.0	
Female	1	N.M.I.	No	ATP6V1B1	Simple het: c.[196G>A]+[=]	p.[Val66Ile]+[=]						12.1	82.1	-3.18	35	2.6	3	86	CKD-2	24 Citrate	No	Yes	Yes	Yes	Yes	2 No	2.0	
Male	0.5	N.M.I.	No									11	82	-3.81	20.5	4.5	3	146	CKD-1	20 Citrate	Yes	No	Yes	No	No	No	2.5	
Female	0.5	N.M.I.	No									18	105	2.66	31	2.7	3	124	CKD-1	23 Citrate	No	Yes	Yes	No	No	No	2.5	
Female	0.1	N.M.I.	No	ATP6VOA4	Simple het: c.[292-1G>A]+[=]	p.[?]+[=]						16	100.5	0.39	27.4	12.8	3.8	134	CKD-1	23 Both		Yes	No	No	No	No	3.7	
Male	0	N.M.I.	No	ATP6V1B1	Simple het: c.[1181G>A]+[=]	p.[Arg394Gln]+[=]						12.3	95	-1.78	53	3.3	4	65	CKD-2	19 Both	No	No	Yes	Yes	No	No	4.0	
Male	0.1	N.M.I.	No	ATP6V1B1								20.8	106.3	-0.1	26.5	7.2	4.6	146	CKD-1	27 Both	No	Yes	Yes	No	No	No	4.5	
Male	0.16	N.M.I.	No		Simple het: c.[1185delC]+[=]	p.[Tyr396Thrfs*12]+[=]						18	105.5	-0.22	53	4.1	4.7	73	CKD-2	21 Both	No	No	Yes	No	No	No	4.5	
Male	0.25	N.M.I.	AR	ATP6VOA4	Simple het: c.[1394G>A]+[=]	p.[Arg465His]+[=]						19.6	119.5	-0.38	28	2.4	7	156	CKD-1	25 Both	Yes	No	Yes	No	No	No	6.8	
Female	1	N.M.I.	AR	ATP6V1B1								22	118	-0.69	44.2	7.3	7	97	CKD-1	22 Both	Yes	No	No	No	No	No	6.0	
Male	3	N.M.I.	No									21	117	-1.97	47.7	5.1	8	90	CKD-1	24 Citrate	No	Yes	Yes	No	Yes	Yes	4	
Male	1.5	N.M.I.	No		Distal trisomy 17q	(46, XX, der(9)t(9;17) ?						27.7	124	-0.72	43	4.2	8	105	CKD-1	20.5 Both	No	No	No	No	No	No	5.0	
Female	4	N.M.I.	No		(mosaicism /46 XX [12])	trisomy 17q (q34.3;q21) [10]						14.5	101	-5.54	34	1.2	8.5	108	CKD-1	28.8 HCO3	No	Yes	Yes	No	Yes	4 No	4.5	
Male	5	N.M.I.	AR	ATP6V1B1	Simple het: c.[1276G>A]+[=]	p.[Val426Met]+p.?						26	130	-0.61	51.2	0.8	9	93	CKD-1	26 HCO3	No	Yes	Yes	No	Yes	Yes	4.0	
Male	4	N.M.I.	No									24	121	-2.12	66.3	3.8	9	67	CKD-2	25 Citrate	Yes	No	Yes	Yes	Yes	5 No	5.0	
Male	0	N.M.I.	No									28.1	152.5	2.99	61	1.6	9	91	CKD-1	25.2 Both	No	Yes	Yes	No	Yes	No	9.0	
Female	1.5	N.M.I.	No		Simple het: c.[340C>T]+[=]	p.[Arg114*]+p.?						35.8	145	0.99	49	2	10	108	CKD-1	25 Both	No	Yes	No	No	No	No	8.5	
Female	0	N.M.I.	AR	ATP6V1B1								41	160	2.13	46	0.7	11	127	CKD-1	25.7 Citrate		No	No	No	No	No	No	11.0
Female	1	N.M.I.	No									36.2	142.1	-0.31	46	1	11	113	CKD-1	25.4 Citrate	No	Yes	Yes	No	No	No	No	10.0
Female	9	N.M.I.	No									42	144	-0.04	41.5	3.3	11	127	CKD-1	31.3 Both	No	Yes	Yes	No	No	No	No	2.0
Male	0.08	N.M.I.	No		Simple het: c.[523G>A]+[=]	p.[Gly175Ser]+[=]						52	151	-0.29	54	0.7	12.6	102	CKD-1	25 HCO3	No	Yes	No	No	No	No	No	12.5
Female	2	N.M.I.	No	ATP6VOA4	Simple het: c.[1181G>A]+[=]	p.[Arg394Gln]+[=]						33	142	-2.2	34	1.1	13	152	CKD-1	24 HCO3	Yes	No	No	No	No	No	No	11.0
Male	N.M.I.	No	ATP6V1B1									39.8	155	-0.18	51	2.7	13	111	CKD-1	22 Citrate	No							

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last		eGFR (mEq/ μmol/L) kg/day	CKD Follow Up	Stages I-V	HCO ₃ ⁻ (mmol/L)	Hyper- Treatment		Metabolic calciuria Control	Nephro- calcinosis	Nephro- lithiasis	Hearing loss		Hearing prescription (age)	Cochlear Implantation	Cochlear Implantation (years)	Time of FU (years)	
										Creatinine (mEq/ μmol/L)	Follow (ml/ min)	eGFR Up	CKD-2																
Female	0.3 N.M.I.	No		Simple het: ATP6V1B1	c.[1181G>A]+[=]	p.[Arg394Gln]+[=]				77.5	163	-0.05	69	0.8	28	87.9	CKD-2	19	Citrate	No	No	Yes	No	No	No	No	No	No	27.7
Female	26 N.M.I.	No		Simple het: ATP6VOA4	c.[2035G>T]+[=]	p.[Asp679Tyr]+[=]				50	160	-0.52	85.7	0.4	34	65.8	CKD-2	21.8	Citrate	Yes	No	Yes	Yes	Yes	No	No	No	No	8.0
Male	3 N.M.I.	No		ATP6V1B1	c.[1181G>A]+[=]	p.[Arg394Gln]+[=]				72	165	0.26	101.7	0.8	43	69.4	CKD-2	30.5	Citrate	No	Yes	Yes	Yes	Yes	No	No	No	No	40.0
Female	22 N.M.I.	No								54	168	0.72	81.3	0.7	43	66.7	CKD-2	19	Citrate	No	No	No	No	No	No	No	No	No	21.0
Female	1 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				12	81	-1.47	32	2.5	2	92	CKD-1	23	Both	No	Yes	Yes	No	No	No	No	No	No	1.0	
Female	1 SLC4A1	AD	h	c.[1627-3C>T]+[=]	p.[?]+[=]				12.5	89	-0.88	33	2.9	2.8	98	CKD-1	21.8	HCO3	No	No	Yes	No	No	No	No	No	No	1.8	
Female	1.5 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				12.6	88.5	-0.88	23	3.3	2.8	140	CKD-1	23.7	Both	No	Yes	Yes	No	No	No	No	No	No	1.3	
Male	1.4 SLC4A1	AR	H	c.[2573C>A]	p.[Ala858Asp]+				11.1	99.5	-0.96	30	4.9	4.2	120.8	CKD-1	18	Citrate	Yes	No	Yes	No	No	No	No	No	No	2.8	
Female	4 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				20.6	110.5	-0.79	39	3.4	6	103	CKD-1	23	Citrate	No	Yes	Yes	No	No	No	No	No	No	2.0	
Male	2.5 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				18	108.5	-1.31	26.5	1.9	6	149	CKD-1	23.4	Both	No	Yes	Yes	No	No	No	No	No	No	3.5	
Male	3 SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]				26	126	2.06	43	2.8	6	107	CKD-1	25	Citrate	No	Yes	Yes	No	No	No	No	No	No	3.0	
Female	2.1 SLC4A1	AR	H	c.[2573C>A]	p.[Ala858Asp]+				12	106	-1.94	45	6.0	6.1	86.0	CKD-2	19	Citrate	Yes	No	Yes	No	No	No	No	No	No	4.0	
Female	2.1 SLC4A1	AR	H	c.[2573C>A]	p.[Ala858Asp]+				15.6	106	-2.27	54	5.8	6.4	71.6	CKD-2	23	Citrate	Yes	No	Yes	No	No	No	No	No	No	4.3	
Female	1 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				19.1	117	-0.88	34	3.1	7	126	CKD-1	23	HCO3	No	Yes	No	No	Yes	Yes	4 No	6.0	6.0		
Female	2 SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]				39	132	1.76	48	1	7	100	CKD-1	21	Both	No	No	Yes	Yes	No	No	No	No	5.0		
Male	0.08 SLC4A1	AD	h	c.[1103_1119del]+[=]	p.[Pro368Argfs*20]+				22.1	122	-0.56	79.6	1.1	7.5	56	CKD-3	18.7	Citrate	Yes	No	Yes	Yes	Yes	Yes	Yes	5 No	7.4		
Female	1 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				25	133	0.86	48.6	1.9	8	100	CKD-1	23.1	HCO3	No	Yes	Yes	No	No	No	No	No	7.0		
Female	3 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				31	135.5	0.46	34	2.7	9	145	CKD-1	23	Both	No	Yes	Yes	No	No	No	No	No	6.0		
Female	0.6 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				28.8	140.5	0.68	50	3.1	9.7	103	CKD-1	20.5	Citrate	No	No	Yes	No	No	No	No	No	9.1		
Female	0.25 SLC4A1	AD	h	c.[1165_1181del]+[=]	p.[Pro368Alafs*10]+				24	127	-1.72	53	0.5	10	87	CKD-2	24.5	Citrate	No	Yes	Yes	No	No	No	No	No	9.8		
Male	7 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				32.9	141.5	0.48	53	1.5	10	97	CKD-1	23	Citrate	No	Yes	Yes	No	No	No	No	No	3.0		
Male	2 SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]				32	138	-0.12	68	1.1	10	74	CKD-2	21.7	Citrate	No	No	No	Yes	No	No	No	No	8.0		
Female	8 SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]				39.3	138	-1.81	46	2	12	110	CKD-1	24.6	Citrate	No	Yes	Yes	No	No	No	No	No	4.0		
Male	4 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				48.1	148	-2.51	83	4.4	14.9	65.1	CKD-2	22	Citrate	No	Yes	Yes	No	No	No	No	No	10.9		
Female	6 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				54	163	0.17	64.5	0.9	15	92	CKD-1	23	HCO3	No	Yes	Yes	No	No	No	No	No	9.0		
Male	8.7 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				56.6	175.5	0.77	70.7	1.5	15	91	CKD-1	23.8	Both	No	Yes	Yes	Yes	No	No	No	No	6.3		
Female	5 SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]				51.3	157.8	-0.71	89.1	1.9	16	65	CKD-2	21.8	Citrate	No	No	Yes	No	No	No	No	No	11.0		
Male	5 SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				37.4	147.6	-3.19	76	2.7	16	71	CKD-2	22	Citrate	No	Yes	Yes	No	No	No	No	No	11.0		
Male	13 SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]				68.1	173	-0.08	75.1	0	16	84	CKD-2	20.7	Nill	No	No	Yes								

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD Follow Up		Hyper- HCO ₃ ⁻		Metabolic Treatment		Nephro- calciuria Control		Hearing loss		Hearing aids		Cochlear Implantation		Cochlear Implantation Time prescription of FU (years)	
										Creatinine (mEq/ μmol/L)	kg/day)	min	I-V	(ml/L)	Stages	(mmol/L)	Treatment	Hyper-	Metabolic	Nephro-	Nephro-	Hearing	Hearing	prescription	Cochlear	Implantation	Implantation		
Female	33	SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]	117			94	0.3	40	57.2	CKD-3	19	Citrate	No	No	Yes	Yes	No	No	No	No	No	No	7.0		
Male	2	SLC4A1	AD	h	c.[1765C>T]+[=]	p.[Arg589Cys]+[=]	80			132	0.9	48	50.2	CKD-3	26	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	46.0		
Male	4	SLC4A1	AD	h	c.[1825>A]+[=]	p.[Gly609Arg]+[=]	33.5	140.5	-5.01	159.1	8.1	51	40	CKD-3	21.3	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	47.0		
Female	8	SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]	80.4			94	0.2	54	53.8	CKD-3	19	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	46.0		
Female	35	SLC4A1	AD	h	c.[1838C>T]+[=]	p.[Ser613Phe]+[=]	55.4			69	0.4	54	76.9	CKD-2	24	Citrate	No	Yes	Yes	Yes	No	No	No	No	No	No	19.0		
Male	16	SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]	85			198	0.3	67	29.4	CKD-4	21	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	51.0		
Male	40	SLC4A1	AD	h	c.[1766G>A]+[=]	p.[Arg589His]+[=]				114		70	55.1	CKD-3	21	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	30.0		
Male	0	Untested	No				4.3	58	2.02	55.3	7	0	38	CKD-3	25.9	HCO3	No	No	No	No	No	No	No	No	No	No	0.0		
Male	0	Untested	No				9.2	68	0.05	13.3	3.9	0.5	187	CKD-1	26.6	Citrate	No	Yes	Yes	No	No	No	No	No	No	No	0.5		
Female	0.6	Untested	No				6.6	65	-2.39	30	2.6	0.9	79	CKD-2	21.3	HCO3	Yes	No	No	No	No	No	No	No	No	No	0.3		
Female	0.2	Untested	No				5.5	65	-2.39	20.3	1.8	0.9	117	CKD-1	16.3	Citrate	No	No	Yes	No	No	No	No	No	No	No	0.7		
Male	0.17	Untested	No				8.7	68	-3.04	17.8	3.2	1	139	CKD-1	21.2	Citrate	No	No	Yes	No	No	No	No	No	No	No	0.8		
Female	0.5	Untested	No				10.4	80	1.95	23	7.2	1	127	CKD-1	18.5	Both			Yes	No	Yes	Yes	0.8	No	0.5				
Male	0.9	Untested	No				7.2	68.5	-3.68	37.1	5.1	1.3	67	CKD-2	17.9	HCO3	No	No	Yes	No	No	No	No	No	No	No	0.4		
Male	0.1	Untested	No				8.4	74	-1.83	30.9	2.3	1.3	87	CKD-2	18	Both	No	No	Yes	No	No	No	No	No	No	No	1.2		
Female	0.25	Untested	No				10.1	76	-1.47	35	9.5	1.5	79	CKD-2	15.5	HCO3	No	No	Yes	No	No	No	No	No	No	No	1.3		
Male	1.3	Untested	No				10	68.5	-4.79	34.5	1	1.7	72	CKD-2	21	Citrate	No	No	Yes	No	No	No	No	No	No	No	0.4		
Male	0.5	Untested	No				8.2	76.7	-2.21	21	7.3	1.7	133	CKD-1	27	Citrate	No	Yes	Yes	No	No	No	No	No	No	No	1.2		
Male	0	Untested	No				15	88	1.11	25	1.4	1.7	128	CKD-1	20.1	Both	No	No	Yes	No	No	No	No	No	No	No	1.7		
Male	0	Untested	No				16	104	3.2	27.2	1.6	2	140	CKD-1	24.9	HCO3	No	No	No	No	No	No	No	No	No	No	2.0		
Male	0.5	Untested	No				10	79	-2.45	68	5	2	42	CKD-3	19	HCO3	No	No	No	No	No	No	No	No	No	No	1.5		
Male	0.6	Untested	No				10.8	81	-1.88	23	3.9	2	129	CKD-1	21.8	HCO3	No	No	Yes	Yes	No	No	No	No	No	No	1.4		
Female	0.6	Untested	No				14	87	0.23	35	3.8	2	91	CKD-1	17.5	Citrate	Yes	No	Yes	No	Yes	Yes	Yes	3	No	1.4			
Male	0.3	Untested	No				10	79	-2.45	44.2	5	2	65	CKD-2	18.5	Both	No	No	Yes	No	No	No	No	No	No	No	1.7		
Male	1	Untested	No				8.1	80	-2.16	38.8	3.7	2	75	CKD-2	18.8	Both	No	No	Yes	No	No	No	No	No	No	No	1.0		
Female	0.1	Untested	No				11.2	84	-1.09	43	3.8	2.3	71	CKD-2	22.3	HCO3	No	Yes	No	No	No	No	No	No	No	No	2.2		
Male	0.12	Untested	No				9.2	85.5	-1.08	43.3	4.9	2.4	72	CKD-2	19	HCO3	No	No	No	No	No	No	No	No	No	No	2.3		
Female	0.2	Untested	No				12.3	89	-0.35	25	1.5	2.5	130	CKD-1	18.1	HCO3			Yes	No	Yes	Yes	Yes	No	No	No	No	No	2.3
Female	0.5	Untested	No				10.4	81	-2.5	22	5.4	2.5	134	CKD-1	25.1	HCO3	No	Yes	No	No	No	No	No	No	No	No	2.0		
Female	0.4	Untested	No				11.3	84.2	-1.69	19	5.1	2.5	162	CKD-1	21.8	Both	No	No	No	No	No	No	No	No	No	No	2.1		
Female	0.5	Untested	No				9.3	85	-1.77	46	2.2	2.7	67	CKD-2	16.5	Citrate	No	No	Yes	No	No	No	No	No	No	No	2.2		
Male	0.4	Untested	No				9.4	84.3	-2.6	27	10.7	2.8	114	CKD-1	20.7	Both	No	No	Yes	No	No	No	No	No	No	No	2.4		
Female	0.5	Untested	No				10.5	83	-2.91	39.8	7.6	3	76	CKD-2	19.9	HCO3	No	No	Yes	No	No	No	No	No	No	No	2.5		
Male	2	Untested	No				15																						

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD		Hyper- calciuria	Metabolic Treatment	Nephro- calcinosis	Nephro- lithiasis	Hearing aids		Cochlear Implantation (years)	Cochlear Implantation prescription of FU (years)		
										Creatinine (mEq/ μmol/L)	Follow kg/day	Up	min	I-V	HCO ₃ ⁻ (mmol/L)	Treatment	Control	Yes	No	Yes	Yes				
Female	0.1	Untested	No				19	115	0	37.1	2.4	6	113	CKD-1	24.3	Citrate		Yes	No	Yes	Yes	4	No	5.9	
Female	2	Untested	No				14.5	92	-5.09	54.8	2.1	6	61	CKD-2	22	Citrate	Yes	No	Yes	No	No	No	No	4.0	
Female	3.5	Untested	No				17	108	-2.27	48.6	2.8	6.7	81	CKD-2	19.1	HCO3	No	No	Yes	No	No	No	No	3.2	
Male	4.1	Untested	No				17.3	107.7	-2.26	35.4	5.2	6.7	111	CKD-1	22.5	Citrate	No	Yes	Yes	No	Yes	Yes	4.2	No	2.6
Female	7	Untested	No				15.3	108	-2.67	32	2	7	123	CKD-1	20	HCO3	No	No	Yes	No	No	No	No	0.0	
Female	0.6	Untested	No				31	131.5	1.76	44.2	2.6	7	109	CKD-1	24	Citrate	No	Yes	No	No	No	No	No	6.4	
Male	1	Untested	No				18.8	114	-1.49	35.4	245.7	7	118	CKD-1	21.6	Both	No	No	Yes	No	No	No	No	6.0	
Female	6	Untested	No				14	90	-6.86	30	6.4	7	110	CKD-1	22	Both	No	Yes	Yes	No	No	No	No	1.0	
Female	5.2	Untested	No				17	105	-3.85	26.5	4.2	7.5	145	CKD-1	20.5	HCO3	No	No	Yes	No	No	No	No	2.3	
Female	0.01	Untested	No				22.3	121.5	-0.6	70.7	0.8	7.6	63	CKD-2	22	Citrate	No	Yes	Yes	No	No	No	No	7.6	
Female	0.1	Untested	No				28	121	-1.2	42.4	2.3	8	104	CKD-1	23.3	Citrate	No	Yes	Yes	No	No	No	No	7.9	
Female	0	Untested	No				19.5	118	-1.75	44.2	3.6	8	97	CKD-1	21	Both	No	No	Yes	No	No	No	No	8.0	
Male	0	Untested	No				27	126	-0.37	65	2.1	8	71	CKD-2	21.2	Both	No	No	Yes	Yes	No	No	No	8.0	
Male	0.25	Untested	No				22.8	127	-0.44	46.9	1.3	8.3	99	CKD-1	26	Citrate	No	Yes	Yes	No	No	No	No	8.0	
Female	4.5	Untested	No				21.5	123	-1.29	62	2.5	8.5	72	CKD-2	19.5	Citrate	No	No	Yes	No	No	No	No	4.0	
Female	0.5	Untested	No				23	120	-1.82	46.9	1.6	8.5	93	CKD-1	25	Citrate	No	Yes	Yes	No	No	No	No	8.0	
Female	1.1	Untested	No				37	135	0.72	44	4.9	8.5	112.0	CKD-1	19	Citrate	No	No	Yes	No	No	No	No	7.4	
Male	3	Untested	No				30	135	0.2	48.6	3.6	9	101	CKD-1	22.4	Citrate	Yes	No	No	No	No	No	No	6.0	
Male	0.4	Untested	No				23	125	-1.44	35.4	4.5	9	129	CKD-1	21.5	Citrate	No	No	Yes	No	Yes	Yes	0.4	No	8.6
Male	8	Untested	No				29	124	-1.61	22.9	2.8	9	198	CKD-1	23.9	Citrate	No	Yes	Yes	Yes	Yes	Yes	No	1.0	
Female	0.5	Untested	No				17.9	100	-6.03	30	6.7	9	122	CKD-1	21	Both	No	No	Yes	No	No	No	No	8.5	
Female	0.33	Untested	No				29.5	138.5	0.12	49.5	2.8	10	102	CKD-1	22.9	Citrate	No	Yes	Yes	No	No	No	No	9.7	
Female	0.1	Untested	No				53.6	141	0.41	48.6	1.7	10	106	CKD-1	24	Both		Yes	No	No	No	No	No	No	9.9
Male	0.1	Untested	No				50	153	2.09	41	1.2	10	136	CKD-1	20.7	Both	No	No	Yes	No	No	No	No	9.9	
Male	0.24	Untested	No							55		10	0	CKD-5	24.2	Both	No	Yes	Yes	No	Yes	Yes	1	No	9.8
Male	0.4	Untested	No				44.8	140.7	-0.16	56	2.9	10.7	92	CKD-1	24.6	Citrate	No	Yes	Yes	No	No	No	No	10.3	
Male	5	Untested	No				19.1	118.5	-3.76	53	6.7	11	82	CKD-2	14.6	HCO3	No	No	Yes	No	No	No	No	6.0	
Female	0	Untested	No				30.2	138.7	-0.73	38	2	11	133	CKD-1	24	HCO3	No	Yes	Yes	No	No	No	No	11.0	
Male	0.1	Untested	No				47	150	0.5	65	1.9	11.5	84	CKD-2	21.3	Both	No	No	Yes	No	Yes	No	No	11.4	
Male	1	Untested	No				26.5	128.5	-2.54	35.6	1.8	11.6	132	CKD-1	21.8	HCO3	Yes	No	No	Yes	No	No	No	10.6	
Male	0.2	Untested	No				39	136	-1.83	48.6	0.6	12	102	CKD-1	23.2	HCO3	No	Yes	Yes	Yes	No	No	No	11.8	
Male	4	Untested	No				26	127	-3.13	65.7	0.8	12	71	CKD-2	26	Citrate	Yes	No	Yes	Yes	Yes	Yes	7	No	8.0
Male	8	Untested	No				30	134.5	-1.97	62	3.2	12	79	CKD-2	17	Citrate	Yes	No	Yes	No	No	No	No	4.0	
Female	11	Untested	No				44.5	149	-0.34	70.7	1.8	12	77	CKD-2	19.5	Citrate	No	No	Yes	Yes	No	No	No	1.0	
Female	0.58	Untested	No				42.2	140.5	-1.89	53	0.4	12.5	97	CKD-1	18.7	Citrate	No	No	Yes	Yes	No	No	No	11.9	
Male	0.7	Untested	No				54.3	156	-0.05	53	1.9	13	107	CKD-1	20.5	Citrate	No	No	No	No	No	No	No	12.3	
Female	2	Untested	No				40	155	-0.34	75	1.2	13	75	CKD-2	21	Both	No	No	Yes	No	No	No	No	11.0	
Male	0.5	Untested	No				30	148	-1.07	62	7.1	13	87	CKD-2	18	Both	Yes								

Gender	Age Diagnosis (year)	Gen	Inheritance	Trait	c.DNA	Protein result	Weight (kg)	Height (cm)	Height SDS	Alkali serum dose		Age at last eGFR		CKD		Hyper- calciuria	Metabolic	Nephro- calcinosis	Nephro- lithiasis	Hearing aids		Cochlear Implantation (years)	Cochlear Implantation prescription (years)	Time of FU (years)		
										Creatinine (mEq/ μmol/L)	kg/day)	Follow Up	(ml/ min)	Stages I-V	HCO ₃ ⁻ (mmol/L)	Treatment	Control	Hearing loss	Hearing prescription (age)							
Male	7	Untested	No				60	168	-1.13	98	1	18	62.6	CKD-2	22.1	Both	No	Yes	Yes	No	No	No	No	No	11.0	
Female	0.5	Untested	No				61.5	161	-0.33	60.1	1.8	18	97.8	CKD-1	22.1	Both	No	Yes	Yes	No	No	No	No	No	17.5	
Male	3	Untested	No				61	174	-0.3	73	0.8	18	87	CKD-2	24	Both	No	Yes	Yes	Yes	Yes	Yes	14	No	15.0	
Male	Untested	No					62.1	169.3	-1.03	75	1.5	18.5	82.4	CKD-2	19	Both	No	No	Yes	Yes	Yes	Yes	Yes	Yes	10	
Male	2.3	Untested	No				67.7	173.4	-0.5	96	3.4	18.9	65.9	CKD-2	20.2	Citrate	No	No	Yes	No	No	No	No	No	16.6	
Male	0.25	Untested	No				72.7	169.5	-0.92	89	1.7	19	69.5	CKD-2	14	Both			Yes	Yes	Yes	Yes	Yes	3.3 Yes	9.5	
Female	0	Untested	No				60.7	162	-0.21	61	0.3	20	108.5	CKD-1	21	Citrate			Yes	No	No	No	No	No	20.0	
Female	16	Untested	No				58	164	0.1	59	0.7	20	112.7	CKD-1	20.6	Citrate			Yes	Yes	No	No	No	No	4.0	
Male	2	Untested	No							96		21	85.8	CKD-2	20.8	Citrate	No	No	Yes	No	Yes	Yes	Yes	2 No	19.0	
Female	6	Untested	No				52	162	-0.21	77	1.4	26	78.6	CKD-2	26.3	HCO3	No	Yes	Yes	No	No	No	No	No	20.0	
Female	0.13	Untested	No				67	156	-1.13	72	0.7	27	84.3	CKD-2	19	HCO3	No	No	Yes	Yes	Yes	Yes	Yes	3 No	26.9	
Male	0.12	Untested	No							99		28	78.1	CKD-2	17.2	Citrate	No	No	Yes	Yes	Yes	Yes	Yes	4	27.9	
Male	7	Untested	No				113	168	-1.23	70.7	0.2	28	115.1	CKD-1	21	Citrate	No	No	Yes	Yes	Yes	Yes	Yes	20 No	21.0	
Female	0.08	Untested	No				54.5	170.5	1.19	81	1.1	28	73	CKD-2	26.4	Citrate	No	Yes	Yes	No	Yes	Yes	Yes	26 No	27.9	
Female	0.01	Untested	No				60			88.4	2	29	65.6	CKD-2	19.8	Citrate	No	No	Yes	Yes	Yes	Yes	No	No	29.0	
Female	2	Untested	No				61.5	160	-0.52	160	1.8	31	32.6	CKD-3	22.5	Both	Yes	No	Yes	Yes	Yes	Yes	No	No	29.0	
Female	1	Untested	No				55	160	-0.52	105	1.2	34	52	CKD-3	22	Both	No	Yes	No	Yes	No	No	No	No	33.0	
Male	0.1	Untested	No				77	175	1.91	121.1	1.8	37	58.5	CKD-3	21	Citrate	No	No	Yes	No	Yes	No	No	No	36.9	
Female	28	Untested	No				52.5	162	-0.21	96	1.4	39	56.1	CKD-3	18	Citrate	No	No	Yes	No	No	No	No	No	11.0	
Female	29	Untested	No				70	170	1.03	70	1	45	78.5	CKD-2	23	Both	No	Yes	No	Yes	No	No	No	No	16.0	
Female	35	Untested	No				50	165	0.26	177	2.1	47	26.7	CKD-4	16.4	HCO3			Yes	Yes	No	No	No	No	No	12.0
Female	41	Untested	No							89		47	59	CKD-3	24	Citrate			Yes	No	No	No	No	No	6.0	
Female	49	Untested	No				68			65.4	0.3	49	83.4	CKD-2	22	Citrate	No	Yes	No	Yes	No	No	No	No	0.0	
Female	50	Untested	No				79	170	1.03	70	0.3	55	75.4	CKD-2	17	Citrate	Yes	No	Yes	No	No	No	No	No	5.0	
Female	54	Untested	No				62			88.4	0.3	58	56.9	CKD-3	24	Citrate	No	Yes	No	Yes	No	No	No	No	4.0	

Supplemental Table 6. Treatment formulary.


Listed are the formulations of alkali supplementation reported by the submitting clinicians and the conversion of the variously reported dosages of citrate/bicarbonate (ml, mg, sachets etc.) into molar equivalents of alkali.

SALTS	COMMERCIAL NAMES	FORMULATION	DOSE	ALKALI MMOLS	ALKALI EQUIVALENTS
Na-Citrate	Bicitra®, Oracit®, Cytra-2®, Shohl's	Oral Solution	1mL	0.33 mmols of Citrate	1 mEq
K-Citrate	Cytra K®	Tablets / sol.	1100mg / 5mL	3.3 mmols of Citrate	10 mEq
	Cytra K®	Crystals	3300mg	10 mmols of Citrate	30 mEq
	CitraK® Forte	Sachets	2g	7.5 mmols of Citrate	22.5 mEq
	Acalka®, Urocit-K®	Tablets	1080mg	3.3 mmols of Citrate	10 mEq
	Uralyt Urate®	Granules	2.5g	6.6 mmols of Citrate	20 mEq
	Kalium-Verla®	Granules	5.4g	6.6 mmols of Citrate	20 mEq
	Urokit®	Sachets	3g	10 mmols of Citrate	30 mEq
	BioKCit®	Sachets	3.5g	5 mmols of Citrate	15 mEq
Na-Citrate + K-Citrate	BioKCit Forte®	Sachets	4.7g	6.66 mmols of Citrate	20 mEq
	Polycitra LC®, Tricitrates®, Cytra-3®	Oral Solution	5 mL (550mg K-Citrate + 500mg Na-Citrate)	3.3 mmols of Citrate	10 mEq
	Uralyt-U®	Granules	2.5g	9 mmols of Citrate	27 mEq
	FONCITRIL 4000®	Sachets	(1.73g K-Citrate + 1.845g Na-Citrate)	5.33 mmols of Citrate	16 mEq
K-Bicarbonate + K-Citrate	ADV7103® 24mEq (also 8mEq)	Sachets	3660mg sachet	16 mmols of Bicarbonate + 2.61 mmols of Citrate	24 mEq
	Kalinor®	Effervescent tablets	1 tablet (2.17g K-Citrate + 2g KHCO ₃)	6.6 mmols Citrate + 20 mmols of Bicarbonate	40 mEq
K-Bicarbonate + Na-Citrate	Blemaren® N	Effervescent tablets	1 tablet	10 mmols of Bicarbonate + 3.3 mmols of Citrate	20 mEq
K-Citrate + Na-Bicarbonate/Carbonate	Blanel®	Effervescent tablets	1 tablet	5 mmols of Citrate + 15 mmols of HCO ₃ ⁻¹ /CO ₃ ²⁻	30 mEq
K-Citrate + Mg-Citrate	Basica Vital E®	Sachets	5.5g	9.33 mmols of Citrate	28 mEq
	LITHOS® Prevent	PR Tablets	1 tablet (757mg K-Citrate + 358mg Mg-Citrate)	3.5 mmols of Citrate	10.5 mEq
	LITHOS® Dissolve	PR Tablets	1 tablet (1514mg K-Citrate + 581mg Mg-Citrate)	7 mmols of Citrate	21 mEq
	Lithos®	Sachets	4.5g	7 mmols of Citrate	21 mEq
	BioKMag®	Sachets	4.5g	7 mmols of Citrate	21 mEq
Mg-Citrate + Ca-Citrate	Cal-Mag Citrate®	Effervescent powder	5.4g (500mg Ca-Citrate + 200mg Mg-Citrate)	7mmols of Citrate	21 mEq
Mg-Citrate	Magnesium Diasporal 300mg®	Sachets	5g	8.3 mmols of Citrate	25 mEq
	Magnesium Diasporal 100mg®	Tablets		2.66 mmols of Citrate	8 mEq
Mg-Citrate + K-Citrate	Lithoren®	Sachets	1 sachet	10 mmols of Citrate	30 mEq
Na-K-Ca-Mg Citrate	Basica Vital®	Powder	16g	5.5 mmols of Citrate	16.5 mEq
Na-Bicarbonate	Nephrotrans®	Tablets	500mg	6 mmols of Bicarbonate	6 mEq
K-Bicarbonate		Tablets	1 g	10 mmols Bicarbonate	10 mEq

Supplemental figures


Supplemental Figure 1. Sodium versus potassium containing alkali supplementation in relation to countries GDP and presence of hypercalciuria.

A) Use of different type of cation in relation to gross domestic product of the countries; sodium containing salts are more frequently used in countries with low GDP, however this difference did not reach a statistical significance level. **B)** Relation between the prevalence of hypercalciuria and the type of cation used, note that patients taking sodium containing alkali did not have more hypercalciuria.




Supplemental Figure 2: CKD stratification and comparison dRTA 2017 vs NHANES III

Patients stratification according to KDIGO CKD Stages and age ranges 20-40 years (**A**) and 40-60 years (**B**). Shown is the prevalence in each CKD group for dRTA and NHANES III cohorts.



Supplemental Figure 3. Age at diagnose of nephrocalcinosis.

Detailed is the age in which nephrocalcinosis was first diagnosed. Note that virtually all patients had nephrocalcinosis when the diagnose of dRTA was made. For comparison see figure 2b (main paper).



Supplemental Figure 4: Age at presentation and per capita GDP

Age at presentation did not differ between the GDP groups. No significant difference was seen suggesting that diagnostic capabilities were similar across the GDP ranges.

